Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 0.64 |
| ▸ | MAX | P61244 | 3/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152657 | 0.89 | PRSS1 (0.53) | MYCMAXEP300HIF1AHCAR3 | |
| SCHEMBL5152664 | 0.89 | PRSS1 (0.53) | MYCMAXEP300HIF1AHCAR3 | |
| SCHEMBL6209803 | 0.89 | PRSS1 (0.53) | MYCMAXEP300HIF1AHCAR3 | |
| SCHEMBL5152661 | 0.89 | PRSS1 (0.53) | MYCMAXEP300HIF1AHCAR3 | |
| SCHEMBL527704 | 0.89 | MYC (0.78) | MYCMAXEP300HIF1AHCAR3 | |
| SCHEMBL17395859 | 0.89 | ALDH1A1 (0.59) | MYCMAXHIF1AXDHTSHR | |
| SCHEMBL7697860 | 0.88 | HCAR3 (0.56) | MYCMAXHCAR3PLA2G4BCASP6 | |
| SCHEMBL7690520 | 0.88 | HCAR3 (0.56) | MYCMAXHCAR3PLA2G4BCASP6 | |
| SCHEMBL4717489 | 0.88 | PDK1 (0.52) | MYCMAXEP300HIF1AXDH | |
| SCHEMBL4718892 | 0.86 | AR (0.67) | MYCMAXEP300HIF1AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452528-B1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| CN-101092400-A | Xanthine oxidase inhibitor | NIPPON CHEMIPHAR CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| CN-100338040-C | xanthine oxidase inhibiting compounds | NIPPON CHEMIPHAR CO (JP) | 2007-09-19 | — | — | CN | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| CN-1615299-A | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1452528-A1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090472-A1 | Xanthine oxidase inhibitors | XDH, CBR1, NOX1 | MYC 4502/4885MAX 1587/4885EP300 2103/4885 |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | XDH, CBR1, NOX1 | MYC 4438/4885MAX 1465/4885EP300 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.